Home > Boards > US Listed > Biotechs > Adaptimunne Therapeutics (ADAP)

ESMO abstract:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
jondoeuk Member Profile
 
Followed By 17
Posts 1,257
Boards Moderated 1
Alias Born 10/24/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 12/16/2020 5:01:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/20/2020 7:37:37 AM
Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During ... GlobeNewswire Inc. - 11/20/2020 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/19/2020 9:10:01 AM
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 9... GlobeNewswire Inc. - 11/19/2020 9:00:00 AM
Adaptimmune to Host Virtual Investor Day on Friday, November 20th GlobeNewswire Inc. - 11/12/2020 8:00:00 AM
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, ... GlobeNewswire Inc. - 11/9/2020 3:18:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2020 4:20:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 7:41:08 AM
Adaptimmune Reports Q3 Financial Results and Business Update GlobeNewswire Inc. - 11/5/2020 7:30:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 11/4/2020 10:42:34 AM
Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020 GlobeNewswire Inc. - 10/22/2020 8:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2020 4:48:05 PM
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial GlobeNewswire Inc. - 10/15/2020 4:40:39 PM
Life-Saving Advancements, Treatments Delivered by Companies Invested in Innovation NetworkNewsWire - 10/2/2020 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2020 10:45:24 AM
Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile a... GlobeNewswire Inc. - 8/28/2020 10:30:10 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 8/10/2020 5:02:42 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 11:17:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 7:38:25 AM
Adaptimmune Reports Q2 Financial Results and Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for... GlobeNewswire Inc. - 7/23/2020 4:00:10 PM
Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020 GlobeNewswire Inc. - 7/22/2020 8:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:13:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 5:10:37 PM
jondoeuk   Monday, 09/14/20 05:26:15 PM
Re: None
Post # of 132 
ESMO abstract:

976TiP - SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer

Background
ADP-A2M4 SPEAR T-cells are genetically engineered to target MAGE-A4+ tumors in HLA-A*02 positive patients (pts). Safety and efficacy for ADP-A2M4 cells have been demonstrated in a phase I trial (NCT03132922). MAGE-A4 is frequently expressed in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Pembrolizumab (pembro), an anti-PD-1 checkpoint inhibitor, monotherapy is approved as 1st-line treatment of r/m HNSCC that expresses PD-L1. The combination of ADP-A2M4 and pembro may result in a synergistic effect due to the inhibition of PD-1 on ADP-A2M4 cells potentially leading to deeper and more durable anti-tumor responses.

Trial design
This single-arm trial will enroll up to 10 pts to evaluate efficacy, safety, and tolerability of ADP-A2M4 with pembro. Checkpoint inhibitor naïve r/m HNSCC pts who are HLA-A*02, MAGE-A4+, and PD-L1 positive (≥1%) will be eligible. Part A is a run-in-phase with pembro as standard-of-care monotherapy followed by Part B, an interventional phase, during which ADP-A2M4 will be administered with pembro post-ADP-A2M4 infusion in patients without response or following progressive disease (PD) with pembro in Part A. Part A: Pts will undergo leukapheresis, and collected T-cells will be transduced with a Lentiviral vector expressing a high affinity MAGE-A4 specific T-cell receptor. Pts will receive pembro monotherapy (200 mg IV) every 3 weeks for a minimum of 3 cycles. Disease status will be assessed at Wk 7. Pts without a response by Wk 7 will proceed to Part B. Pts who respond to pembro after 3 cycles will continue treatment in Part A until PD when they will become eligible for ADP-A2M4 treatment in Part B. Part B: Pts will undergo lymphodepleting chemotherapy w/ fludarabine and cyclophosphamide prior to receiving ADP-A2M4 at a dose range of 1x109 to 10x109 transduced T-cells. Pembro infusions every 3 weeks will re-start after ADP-A2M4 infusion and will continue until PD. A Safety Review Committee will review safety and benefit:risk during Part B. Disease will be assessed by investigators per RECIST v1.1 using CT/MRI scans post T-cell infusion.

Clinical trial identification
NCT03132922.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences